Gene · 23400
Papers1,821
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 1,821
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Lactoferrin: neuroprotection against Parkinson's disease and secondary molecule for potential treatment. | Front Aging Neurosci | 2023 | 37731953 | PubTator, text mining | PubMed |
| The neuroprotective effects of FG-4592, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, against oxidative stress induced by alpha-synuclein in N2a cells. | Sci Rep | 2023 | 37731009 | PubTator, text mining | PubMed |
| Ganoderic Acid A targeting leucine-rich repeat kinase 2 involved in Parkinson's disease-A computational study. | Aging Med (Milton) | 2023 | 37711263 | PubTator, text mining | PubMed |
| Mitochondrial dysfunction in neurodegenerative disorders: Potential therapeutic application of mitochondrial transfer to central nervous system-residing cells. | J Transl Med | 2023 | 37689642 | PubTator, text mining | PubMed |
| Mutational spectrum and clinical features of GBA1 variants in a Chinese cohort with Parkinson's disease. | NPJ Parkinsons Dis | 2023 | 37658046 | PubTator, text mining | PubMed |
| CRISPR/Cas9 genome editing for neurodegenerative diseases. | EXCLI J | 2023 | 37636024 | PubTator, text mining | PubMed |
| Spf1 and Ste24: quality controllers of transmembrane protein topology in the eukaryotic cell. | Front Cell Dev Biol | 2023 | 37635876 | PubTator, text mining | PubMed |
| Inhibition of Protein Aggregation and Endoplasmic Reticulum Stress as a Targeted Therapy for α-Synucleinopathy. | Pharmaceutics | 2023 | 37631265 | PubTator, text mining | PubMed |
| The Molecular Mechanisms of the Relationship between Insulin Resistance and Parkinson's Disease Pathogenesis. | Nutrients | 2023 | 37630775 | PubTator, text mining | PubMed |
| Manganese-Induced Parkinsonism: Evidence from Epidemiological and Experimental Studies. | Biomolecules | 2023 | 37627255 | PubTator, text mining | PubMed |
| Investigation of PRKN Mutations in Levodopa-Induced Dyskinesia in Parkinson's Disease Treatment. | Biomedicines | 2023 | 37626726 | PubTator, text mining | PubMed |
| Neurological Insights into Sleep Disorders in Parkinson's Disease. | Brain Sci | 2023 | 37626558 | PubTator, text mining | PubMed |
| DoSurvive: A webtool for investigating the prognostic power of a single or combined cancer biomarker. | iScience | 2023 | 37609633 | PubTator, text mining | PubMed |
| The involvement of Purkinje cells in progressive myoclonic epilepsy: Focus on neuronal ceroid lipofuscinosis. | Neurobiol Dis | 2023 | 37573956 | PubTator, text mining | PubMed |
| How neurons maintain their axons long-term: an integrated view of axon biology and pathology. | Front Neurosci | 2023 | 37564364 | PubTator, text mining | PubMed |
| Introduction of a multiplex amplicon sequencing assay to quantify DNA methylation in target cytosine markers underlying four selected epigenetic clocks. | Clin Epigenetics | 2023 | 37563670 | PubTator, text mining | PubMed |
| Single-Cell Sequencing in Neurodegenerative Disorders. | Mol Diagn Ther | 2023 | 37552451 | PubTator, text mining | PubMed |
| Mitochondrial Neurodegenerative Diseases: Three Mitochondrial Ribosomal Proteins as Intermediate Stage in the Pathway That Associates Damaged Genes with Alzheimer's and Parkinson's. | Biology (Basel) | 2023 | 37508402 | PubTator, text mining | PubMed |
| Dystonic Opisthotonus in Kufor-Rakeb Syndrome: Expanding the Phenotypic and Genotypic Spectrum. | J Mov Disord | 2023 | 37488066 | PubTator, text mining | PubMed |
| Development of CRISPR Cas9, spin-off technologies and their application in model construction and potential therapeutic methods of Parkinson's disease. | Front Neurosci | 2023 | 37483347 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23400/papers?page=9